Overall, EMT is a loosely defined mechanism of resistance to cetuximab in CRC, but inferences can be made to relate the functions of RAC1, RAC1B, and their contributions to EMT that could contribute to therapy resistance based on evidence from other cancers and CRC. Here, RAC1 is linked to cancer.